Inhibiting the inhibitor: A new route to bone anabolism

Journal of Bone and Mineral Research

Volumn 24, Issue 4, 2009, Pages 575-577

  Jilka, Robert L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; GLUCOCORTICOID; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; SCLEROSTIN; SOMATOMEDIN BINDING PROTEIN; WNT PROTEIN;

BINDING AFFINITY; BIOSYNTHESIS; BONE DEVELOPMENT; BONE GROWTH; BONE MASS; BONE MINERALIZATION; BONE REMODELING; CELL DIFFERENTIATION; DOWN REGULATION; FRACTURE REDUCTION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; NOTE; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OVARIECTOMY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; FEMALE; GENETIC MARKERS; HUMANS; MICE; OSTEOCALCIN; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; RATS; WNT PROTEINS;

EID: 65549097624     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090228     Document Type: Note

References (22)

1. Williams BO, Insogna KL 2009 Where Wnts went: The exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res 24:171-178.
2. Rodda SJ, McMahon AP 2006 Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 133:3231-3244.
3. Li X, Zhang Y, Kang H, Liu W, Liu P. Zhang J, Harris SE, Wu D 2005 Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887.
4. Brunkow ME. Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L. Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J 2001 Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577-589.
5. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W. Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W 2001 Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537-543.
6. Li X. Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D. Kurahara C. Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey L, Simonet WS, Ke HZ, Paszty C 2008 Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860-869.
7. G171V to modulate Wnt activity. J Bone Miner Res 21:1738-1749.
8. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C 2009 Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:000-000.
9. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH 2008 Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283:5866-5875.
10. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL 2005 Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteo-cytes: A novel mechanism for hormonal control of osteo-blastogenesis. Endocrinology 146:4577-1583.
11. Keller H, Kneissel M 2005 SOST is a target gene for PTH in bone. Bone 37:148-158.
12. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling A, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T 2008 Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 3:e2942.
13. Bonewald LF, Johnson ML 2008 Osteocytes, mechanosensing and Wnt signaling. Bone 42:606-615.
14. Manolagas SC 2006 Perspective: Choreography from the tomb: An emerging role of dying osteocytes in the purposeful, and perhaps not so purposeful, targeting of bone remodeling. Bonekey Osteovision 3:5-14.
15. Kramer I, Loots GG, Keller H, Kneissel M 2008 PTH-induced bone mass gain is blunted but not abolished in SOST over-expressing and deficient mice. J Bone Miner Res 23:S12.
16. Jilka RL 2007 Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434-1446.
17. Hodsman AB, Bauer DC. Dempster D, Dian L, Hartley DA, Harris ST, Kendler D, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK 2005 Parathyroid hormone and ter-iparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 26:688-703.
18. Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, Nieves JW, Dempster DW 2006 A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide. J Bone Miner Res 21:366-373.
19. Li X, Warmington K, Niu QT, Asuncion F, Grisanti M, Dwyer D, Tan H, Simonet WS, Ominsky M, Stolina M, Kostenuik PJ, Paszty C, Ke HZ 2008 Effects of co-treatment with an anti-sclerostin monoclonal antibody and alendronate in ovariec-tomized rats. J Bone Miner Res 23:S60.
20. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K 2007 Targeted ablation of osteocytes induces osteoporosis with defective mechano-transduction. Cell Metab 5:464-475.
21. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G 2008 Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825-837.
22. Baron R 2009 Wnt signaling, LRP5 and gut serotonin: Have we been targeting the right pathway for the wrong reasons? 1BMS BoneKEy 6:86-93.